Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 28;28(7):3012.
doi: 10.3390/molecules28073012.

A Brief Review on the Synthesis of the N-CF3 Motif in Heterocycles

Affiliations
Review

A Brief Review on the Synthesis of the N-CF3 Motif in Heterocycles

Zizhen Lei et al. Molecules. .

Abstract

The trifluoromethyl group is widely recognized for its significant role in the fields of medicinal chemistry and material science due to its unique electronic and steric properties that can alter various physiochemical properties of the parent molecule, such as lipophilicity, acidity, and hydrogen bonding capabilities. Compared to the well-established C-trifluoromethylation, N-trifluoromethylation has received lesser attention. Considering the extensive contribution of nitrogen to drug molecules, it is predicted that constructing N-trifluoromethyl (N-CF3) motifs will be of great significance in pharmaceutical and agrochemical industries. This review is mainly concerned with the synthesis of heterocycles containing this motif. In three-membered heterocycles containing the N-CF3 motif, the existing literature mostly demonstrated the synthetic strategy, as it does for four- and larger-membered heterocycles. Certain structures, such as oxaziridines, could serve as an oxidant or building blocks in organic synthesis. In five-membered heterocycles, it has been reported that N-CF3 azoles showed a higher lipophilicity and a latent increased metabolic stability and Caco-2-permeability compared with their N-CH3 counterparts, illustrating the potential of the N-CF3 motif. Various N-CF3 analogues of drugs or bioactive molecules, such as sildenafil analogue, have been obtained. In general, the N-CF3 motif is developing and has great potential in bioactive molecules or materials. Give the recent development in this motif, it is foreseeable that its synthesis methods and applications will become more and more extensive. In this paper, we present an overview of the synthesis of N-CF3 heterocycles, categorized on the basis of the number of rings (three-, four-, five-, six- and larger-membered heterocycles), and focus on the five-membered heterocycles containing the N-CF3 group.

Keywords: N-trifluoromethyl group; heterocycles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Drug analogues containing N-trifluoromethyl motif.
Figure 2
Figure 2
Variably sized N-heterocycles containing the N-trifluoromethyl motif.
Scheme 1
Scheme 1
Synthesis of (a) aziridines, (b) triziridines and (c,d) diaziridines.
Scheme 2
Scheme 2
Synthesis and applications of oxaziridines.
Scheme 3
Scheme 3
Synthesis of oxazetidines through trifluoronitrosomethane.
Scheme 4
Scheme 4
Synthesis of (a) thiazetidine and (b) diazaboretidin through [2+2] cycloaddition reaction.
Figure 3
Figure 3
Synthesis of N-trifluoromethyl compounds to determine their aqueous stability and additional key in vitro properties.
Scheme 5
Scheme 5
Synthesis of N-trifluoromethyl benzotriazole or benzimidazole through fluorine/halogen exchange.
Scheme 6
Scheme 6
Synthesis of N-trifluoromethyl amines from (a) methyl dithiocarbamate or (b) phenyl dithiocarbamate.
Scheme 7
Scheme 7
Synthesis of thiocarbomoyl fluoride intermediate and further oxidative desulfurization and fluorination to access N-trifluoromethyl amines.
Scheme 8
Scheme 8
Synthesis of N-trifluoromethyl compounds through cyclization of fluoro-olefins induced by fluoride ion.
Scheme 9
Scheme 9
Synthesis of oxazolidines or dioxazolidines through [3+2] cycloaddition of perfluorinated oxaziridine.
Scheme 10
Scheme 10
(a) Synthesis of perfluoroalkyl azides; (b) cycloaddition of trifluoromethyl azides with alkynes or ketones; (c) mechanism of the cycloaddition of trifluoromethyl azides with ketones.
Scheme 11
Scheme 11
Synthesis of diverse N-trifluoromethyl heterocycles through transannulation catalyzed by rhodium.
Scheme 12
Scheme 12
Mechanism of transannulation catalyzed by rhodium.
Scheme 13
Scheme 13
Synthesis of N-trifluoromethyl heterocycles through 1,3-dipoles generated by hypervalent iodine reagent with nitriles.
Scheme 14
Scheme 14
Synthesis of other N-trifluoromethyl heterocycles through cyclization of (a) trifluoromethyl isocyanate, (b) trifluoronitrosomethane, (c) trifluoromethyl isocyanide, and (d) N-trifluoromethyl hydrazides.
Scheme 15
Scheme 15
Synthesis of diverse N-trifluoromethyl heterocycles through N-trifluoromethyl carbomoyl building blocks.
Scheme 16
Scheme 16
(a) Synthesis of N-trifluoromethyl oxazolidinones through trifluoromethylamination/cyclization of styrenes or vinyl; (b) Proposed reaction mechanism; (c) estrone analogue 65a; (d) Synthesis of N-trifluoromethyl oxazolidinones through trifluoromethylamination of vinyl acetate 66 and further cyclization; (e) Synthesis of oxazolidinones through cyclization of allenes.
Scheme 17
Scheme 17
(a) Togni’s reagents and trifluoromethylation of benzotriazole; (b) Synthesis of various five-membered N-trifluoromethyl heterocycles through Togni’s reagent; (c) Synthesis of trifluoromethyl amines through Umemoto’s reagents.
Scheme 18
Scheme 18
(a) Synthesis of thiocarbomoyl fluoride intermediate through DAST and CS2 and subsequently Oxidative desulfurization and fluorination; (b) examples of drug analogues obtained by Oxidative desulfurization and fluorination.
Scheme 19
Scheme 19
Synthesis of six-membered N-trifluoromethyl heterocycles through [2+2] cycloaddition: (a) trifluoronitrosomethane with substituted diene; (b) N-trifluoromethyl imines with cyclopentadiene; (c) Trifluoromethyl-substituted N-sulfinylamine with diene and further oxidation.
Scheme 20
Scheme 20
Synthesis of diverse six-membered heterocycles: (a) Dimerization or trimerization of N-trifluoromethyl carbodiimide; (b) Dimerization or trimerization of trifluoromethyl-substituted N-sulfinylamine; (c) direct fluorination of N, N-dimethyl piperidine.
Scheme 21
Scheme 21
Synthesis of larger-membered N-trifluoromethyl heterocycles through addition reaction of dioxyl 80 or its mercurial 84.
Scheme 22
Scheme 22
Synthesis of N-trifluoromethyl azepine and azepinone via rhodium-catalyzed annulation of 1,2,3-triazoles.
Scheme 23
Scheme 23
Synthesis of perfluoro heterocycles through reaction of tetrafluoroformaldazine with oxalyl fluoride or carbonyl fluoride.
Scheme 24
Scheme 24
Synthesis of diverse N-trifluoromethyl heterocycles: (a) pyrolysis of perfluoropiperidine, perfluoromorpholine or perfluorooxazinane; (b) fluorination of 4-methylpyridine in the presence of caesium tetrafluorocobaltate; (c) electrochemical fluorination of various nitrogen-containing materials.

Similar articles

Cited by

References

    1. Zhou Y., Wang J., Gu Z., Wang S., Zhu W., Acena J.L., Soloshonok V.A., Izawa K., Liu H. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chem. Rev. 2016;116:422–518. doi: 10.1021/acs.chemrev.5b00392. - DOI - PubMed
    1. Purser S., Moore P.R., Swallow S., Gouverneur V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008;37:320–330. doi: 10.1039/B610213C. - DOI - PubMed
    1. Tomashenko O.A., Grushin V.V. Aromatic trifluoromethylation with metal complexes. Chem. Rev. 2011;111:4475–4521. doi: 10.1021/cr1004293. - DOI - PubMed
    1. Besset T., Schneider C., Cahard D. Tamed Arene and Heteroarene Trifluoromethylation. Angew. Chem. Int. Ed. 2012;51:5048–5050. doi: 10.1002/anie.201201012. - DOI - PubMed
    1. Vitaku E., Smith D.T., Njardarson J.T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. J. Med. Chem. 2014;57:10257–10274. doi: 10.1021/jm501100b. - DOI - PubMed

LinkOut - more resources